(*shared authorship, **corresponding author)

Illerhaus G, Ferreri AJM, Wendler J, Binder M, Borchmann P, Hasenkamp J, Stilgenbauer S, Röth A, Egerer G, Ernst T, Weber T, Hertenstein B, Lenz G, Dreyling M, Möhle R, Kobbe G, Schmidt CA, Brunnberg U, Panse J, Kneba M, Heinicke T, Schroll S, Larsen TS, Thurner L, Pukrop T, Salwender H, Naumann R, Hess G, Kroschinsky FP, Blystad AK, Keller U, Pulczynski EJ, Pedersen MB, Re F, Orsucci L, Pospiech L, La Rosée P, Deckert M, Ponzoni M, Gmehlin D, Backenstrass M, Jensch A, Valk E, Calimeri T, Kasenda B, Trepel M, Fricker H, Semenova I, Scherer F, von Gottberg P, Burger E, Grishina O, Hader C, Ihorst G, Finke J, Zucca E, Schorb E. High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.
Lancet. 2026 Aug 8;408(10554):532-544. doi: 10.1016/S0140-6736(26)00917-7.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00917-7/fulltext

Adamo S, Rurik JG, Gustafson CE, Buggert M. Memory T cell aging and rejuvenation.
Immunity. 2026 Apr 14;59(4):878-896. doi: 10.1016/j.immuni.2026.02.018.
https://www.cell.com/immunity/fulltext/S1074-7613(26)00088-9

Stein A, Goekkurt E, Al-Batran SE, Moosmann N, Ettrich TJ, Goetze T, Gruen B, Homann N, Lorenzen S, Hofheinz RD, Rempel V, Siegler G, Müller C, Thiele B, Broering T, Cruz MS, Pauligk C, Binder M, Tintelnot J. Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.
Nature Medicine. 2025 Dec;31(12):4197-4204. doi: 10.1038/s41591-025-03979-y.
https://www.nature.com/articles/s41591-025-03979-y

Brandt A, Klinghammer K, Schultheiss C, Paschold L, Wickenhauser C, Bauer M, Bergqvist A, Hahn D, Schafhausen P, Tometten M, Blaurock M, Zech HB, Busch CJ, Dietz A, Müller-Richter U, Alt J, Boehm A, Kowoll S, Steighardt J, Lasch A, Westgaard IH, Westhrin W, Stein A, Hinke A, Binder M. UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial.
MED. 2025 Apr 11:100647. doi: 10.1016/j.medj.2025.100647.
https://www.cell.com/med/fulltext/S2666-6340(25)00074-1

Schultheiß C*, Schmidt-Barbo P*, Paschold L, Esperanzate C, Behn A, Mikolajczyk R, Kastner D, Aksentijevich I, Binder M. Deficiency of adenosine deaminase 2 skews adaptive immune repertoires towards specific sets of T and B cell receptors.
J Allergy & Clinical Immunology. 2025 Feb. 7. doi: 10.1016/j.jaci.2025.01.032.
https://www.jacionline.org/article/S0091-6749(25)00124-1/fulltext

Paschold L*, Schultheiss C*, Schmidt-Barbo P, Klinghammer K, Hahn D, Tometten M, Schafhausen P, Blaurock M, Brandt A, Westgaard I, Kowoll S, Stein A, Hinke A, Binder M. Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer.
NPJ Precision Oncology. 2025 Aug 5;9(1):272. doi: 10.1038/s41698-025-01020-6.
https://www.nature.com/articles/s41698-025-01020-6

Schultheiß C, Paschold L, Mohebiany AN, Escher M, Kattimani YM, Müller M, Schmidt-Barbo P, Mensa-Vilaró A, Aróstegui JI, Boursier G, de Moreuil C, Hautala T, Willscher E, Jonas H, Chinchuluun N, Grosser B, Märkl B, Klapper W, Oommen PT, Gössling K, Hoffmann K, Tiegs G, Czernilofsky F, Dietrich S, Freeman A, Schwartz DM, Waisman A, Aksentijevich I, Binder B. A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors.
Science Advances. 2024 Aug 23;10(34):eadl3975. doi: 10.1126/sciadv.adl3975.
https://www.science.org/doi/10.1126/sciadv.adl3975

Märkl F*, Schultheiß C*, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S, Binder M. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.
Nature Communications. 2024 Feb 2;15(1):993. doi: 10.1038/s41467-024-45378-w.
https://www.nature.com/articles/s41467-024-45378-w

Adamo S, Gao Y, Sekine T, Mily A, Wu J, Storgärd E, Westergren V, Filén F, Treutiger CJ, Sandberg JK, Sällberg M, Bergman P, Llewellyn-Lacey S, Ljunggren HG, Price DA, Ekström AM, Sette A, Grifoni A, Buggert M. Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox
Cell Host & Microbe. 2023 Jun 14;31(6):928-936.e4. doi: 10.1016/j.chom.2023.04.015.
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(23)00166-X

Adamo S, Michler J, Zurbuchen Y, Cervia C, Taeschler P, Raeber ME, Baghai Sain S, Nilsson J, Moor AE, Boyman O. Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection.
Nature. 2022 Feb;602(7895):148-155. doi: 10.1038/s41586-021-04280-x.
https://www.nature.com/articles/s41586-021-04280-x

Stein A*, Paschold L*, Tintelnot J, Gökkurt E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka  S, Al-Batran SA, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hegewisch-Becker S, Binder M. Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive Esophago Gastric Adenocarcinoma – the randomized AIO INTEGA trial.
JAMA oncology. JAMA Oncol. 2022 Jun 23. doi: 10.1001/jamaoncol.2022.2228.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2793712

Stein A*, Simnica D*, Schultheiß C*, Scholz R, Tintelnot J, Goekkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich T, Doerfel S, Al-Batran SE, Karthaus, M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
Journal for Immunotherapy of Cancer. 2021 Jul;9(7):e002844. doi: 10.1136/jitc-2021-002844.
https://jitc.bmj.com/content/9/7/e002844

Porritt RA*, Paschold L*, Rivas MN, Cheng MH, Yonker LM, Chandnani H, Lopez M, Simnica S, Schultheiß C, Santiskulvong C, Van Eyk J, McCormick JK, Fasano A, Bahar I, Binder M**, Arditi M**. HLA Class I-associated expansion of TRBV11-2 T cells in Multisystem Inflammatory Syndrome in Children.
Journal of Clinical Investigation. 2021 May 17;131(10):e146614. doi: 10.1172/JCI146614.
https://www.jci.org/articles/view/146614

Schultheiß C, Simnica D, Willscher E, Oberle A, Fanchi LF, Bonzanni N, Wildner N, Schulze-Zur-Wiesch J, Weiler-Normann C, Lohse AW, Binder M. Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
Hepatology. 2021 Apr;73(4):1436-1448. doi: 10.1002/hep.31473.
https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.31473

Porritt RA, Binek A, Paschold L, Rivas MN, McArdle A, Yonker LM, Alter G, Chandnani HK, Lopez M, Fasano A, Van Eyk JE, Binder M, Arditi M. The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children.
Journal of Clinical Investigation. 2021 Oct 15;131(20):e151520. doi: 10.1172/JCI151520.
https://www.jci.org/articles/view/151520

Schultheiß C*, Paschold L*, Simnica D*, Mohme M, Willscher E, von Wenserski L, Scholz R, Wieters I, Dahlke C, Tolosa E, Sedding DG, Ciesek S, Addo M, Binder M. Next Generation Sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease.
Immunity. 2020 Aug 18;53(2):442-455. doi: 10.1016/j.immuni.2020.06.024.
https://www.sciencedirect.com/science/article/pii/S107476132030279X?via%3Dihub

von Wenserski L, Schultheiß C, Bolz S, Schliffke S, Simnica D, Willscher E, Gerull H, Bobusch A-L, Riecken K, Fehse B, Altfeld M, Nollau P, Binder M. SLAMF receptors negatively regulate B cell rece¬ptor signaling in chronic lymphocytic leukemia via prohibitin-2.
Leukemia. 2020. Apr;35(4):1073-1086. doi: /10.1038/s41375-020-01025-z.
https://www.nature.com/articles/s41375-020-01025-z

Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab.
Blood. 2006 Sep 15;108(6):1975-8. doi: 10.1182/blood-2006-04-014639.
https://ashpublications.org/blood/article/108/6/1975/22609/The-epitope-recognized-by-rituximab